Lataa...
ERα36 as a Potential Therapeutic Target for Tamoxifen-Resistant Breast Cancer Cell Line Through EGFR/ERK Signaling Pathway
BACKGROUND: Acquired tamoxifen resistance is one of the major barriers to the successful treatment of breast cancer. Recently, overexpression of ERα36 was demonstrated to be a potential mechanism for the generation of acquired tamoxifen resistance. This study aims to evaluate the possibility of ERα3...
Tallennettuna:
| Julkaisussa: | Cancer Manag Res |
|---|---|
| Päätekijät: | , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Dove
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6969677/ https://ncbi.nlm.nih.gov/pubmed/32021441 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S226410 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|